AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01132222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen + Pseudoephedrine Hydrochloride
Description: Ibuprofen 200 mg + Pseudoephedrine Hydrochloride 30 mg Tablets
Study NCT01062854 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soft earplugs are worn during sleep study
Description: Subjects are asked to wear earplugs when possible for 3-5 nights prior to their baseline sleep study. On the night of their sleep study they are randomized to either wears earplugs or no earplugs groups.
Study NCT01746199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cotrimoxazole daily prophylaxis
Study NCT01746199 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sulphadoxine-pyrimethamine
Description: Intermittent preventive sulphadoxine-pyrimethamine treatment
Study NCT02797795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NEV801
Description: Dose Escalation
Study NCT01996254 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SPRINT Peripheral Nerve Stimulation (PNS) System
Description: The SPRINT System is an Investigational Device which delivers mild electrical stimulation to nerves in the residual limb. The SPRINT System includes a small wire (called a Lead) that is placed through the skin in the upper leg. It also includes a device worn on the body that delivers stimulation (called the SPRINT Stimulator).
Study NCT00602836 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Cycle 1: 100 mg by IV on day 1, 375 mg/m\^2 by IV on day 2 Cycle 2-6: 375 mg/m\^2 by IV on day 1 (every 21 days)
Study NCT01810406 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CSE with 10 ml EVE
Description: Combined Spinal-Epidural (CSE) with 10 ml Epidural Volume Extension (EVE)
Study NCT01810406 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CSE without EVE
Description: Combined Spinal-Epidural (CSE) without Epidural Volume Extension (EVE)
Study NCT00602836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600 mg/m\^2 by IV on day 1 of cycles 1-6 (every 21 days)
Study NCT00602836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Cycle 7: 5 mg orally daily on days 1-28 Cycle 8: 10 mg orally daily on days 1-28 as tolerability permits Cycle 9 and beyond: 10 mg orally daily on days 1-28
Study NCT00602836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentostatin
Description: 2 mg/m\^2 by IV on day 1 of cycles 1-6 (every 21 days)
Study NCT02760004 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PRogram In Support of Moms (PRISM)
Description: * Access to MCPAP for Moms~* PRogram In Support of Moms Toolkit with Stepped Care Algorithms~* Support clinic specific implementation using the Addressing Problems Through Organizational Change (APTOC) platform~* Customization of depression screening for each practice~* Proactively engage and track all women who screen +ve on the Edinburgh Postnatal Depression Scale(EPDS)~* Employ psychoeducation and Motivational Interviewing to engage patients with depression~* medical assistant champion and psychiatrist contact bi-weekly to review cases~* Stepped care treatment to depression screening/assessment
Study NCT02760004 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MCPAP for Moms
Description: * 30-60 minute presentation on perinatal depression~* Access to telephonic psychiatric consultation with MCPAP for Moms perinatal psychiatrist for Ob/Gyns~* Access to Ob/Gyn provider assessment and treatment recommendations via one-time face-face MCPAP for Moms psychiatrist patient evaluation~* Access to assessment and treatment protocols in Provider Toolkit~* Resource provision/referrals
Study NCT02260765 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: dTMS
Description: The Brainsway H-Coil TMS device is intended for the treatment of depressive episodes in patients suffering from Major Depressive Disorder (MDD). The device technology is based on the application of deep TMS by means of repetitive pulse trains at a determined frequency
Study NCT03486873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 or 400 mg IV infusion
Study NCT03486873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care (SOC)
Description: IV infusion or oral tablets
Study NCT03486873 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (SOC)
Description: IV infusion or oral tablets
Study NCT03486873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Oral capsules
Study NCT03484702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JCAR017
Description: Specified dose on specified days
Study NCT01536756 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention -- Physical Rehabilitation Program
Description: The intervention group will participate in a Physical Rehabilitation Program which includes a 60-minute training session at a frequency of 3 times a week over a total of 12-week duration. The training session consists of 45 minutes of warm-up stretching and circuit training. This includes 3 stations of aerobic exercises for physical work up of different body parts, and 3 stations of strengthening exercises of major muscles groups at 3 sets of 10 repetitions. The final 15-minute training session will be the cooling down exercise with emphasis on stress management incorporating mindful breathing, stretching and body awareness exercise.
Study NCT01536756 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Wait List Control Group
Description: The subjects of the control group will be asked to maintain their usual activities while awaiting for the physical rehabilitation program at the 12-week waiting time. They will be allowed to receive any other usual medical services including social services and psychotherapy but not physiotherapy services. At the end of the 3rd month, the control group will be recruited into the Physical Rehabilitation Program. Patients in the control group will then join in as the intervention group and follow the intervention and assessment protocol.
Study NCT03462329 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotics (preferentially oral doxycycline 100 mg bid)
Description: Patients will be treated with antibiotics for Lyme disease.
Study NCT04253925 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kegel exercises
Description: global postural correction exercises
Study NCT04253925 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kegel exercises
Description: global postural correction exercises
Study NCT00144521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRA(Tocilizumab)
Description: 8mg/kg/4week(i.v.)for 24 weeks
Study NCT00144521 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MRA placebo
Description: 0mg/kg/4week(i.v.) for 24 weeks
Study NCT01618305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine/zidovudine
Description: Participants received one lamivudine 150 mg/zidovudine 300 mg fixed-dose combination tablet twice a day from entry through delivery\*.~\* Participants may have received a locally supplied nucleoside reverse transcriptase inhibitor (NRTI) backbone in place of lamivudine/zidovudine with permission of the protocol team obtained prior to randomization.
Study NCT01618305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: Participants received one 600 mg tablet of efavirenz each night from entry through delivery.
Study NCT01618305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Participants received one 400 mg raltegravir tablet twice a day from entry through delivery.
Study NCT03103581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI4700
Description: BLI4700 Bowel Preparation (Investigational Regimen)
Study NCT01205698 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nutritional drink
Study NCT01205698 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional drink
Study NCT01962883 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic treatment
Description: The following treatment protocol is an outline only; structures will be treated only if the dysfunction was present during the evaluation.~Week 1: Venous Sinuses, diaphragms, major cranial compactions, sphenobasilar symphysis normalization and dural release~Week 2 Non-Physiological without respect of axis dysfunction in cranium, spine, pelvis, ankle. Non-physiological with respect of axis dysfunctions in the cranium. Temporal and orbital sutures.~Week 3 Non-Physiological with respect of axis dysfunction lesions within the spine, pelvis and ankle. Visceral tissues: kidneys, liver, spleen, heart. Cerebral hemisphere and lateral ventricles.~Week 4 Physiological dysfunctions within the cranium, spine, pelvis, and ankle. Myofascial restrictions and muscles of the jaw and eye.
Study NCT00891683 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AEG33773 oral dosing
Description: AEG33773 capsules: subjects will receive a daily dose of either 100 mg, 200 mg, or 400 mg AEG33773. Placebo capsules: subjects will receive a daily dose of placebo (matching test product). Capsules will be taken by mouth, over 28 consecutive days
Study NCT00891683 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AEG33773 oral dosing
Description: AEG33773 capsules: subjects will receive a daily dose of either 100 mg, 200 mg, or 400 mg AEG33773. Placebo capsules: subjects will receive a daily dose of placebo (matching test product). Capsules will be taken by mouth, over 28 consecutive days
Study NCT03599310 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Advance care planning
Description: The ACP guide is adapted from the Serious Illness Communication Guide and a culturally-sensitive ACP programme developed in the local context. The trained ACP facilitators will initiate the conversation by introducing the concepts of ACP with the support of the guide and assessing the patient's illness understanding and readiness to think about end-of-life care issues.
Study NCT03599310 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: In the current practice, patients will have to take the initiative themselves if they would like to discuss their end-of-life care or make an advance directive.
Study NCT01956357 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aquatic exercise
Study NCT01956357 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Land Exercise
Study NCT00400010 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expert System Intervention
Description: Questionnaires on motivation to change and alcohol consumption were assessed in a clinical interview. Data were entered in a Computer and a fully automatized feedback letter was generated by an expert system. The printed feedback letter was handed out to patients by study staff the following day.
Study NCT00440050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHA (Docosahexaenoic Acid)
Description: 950 mg soft-gel capsules which contain approximately 510 mg DHA, 2 capsules twice a day for 18 months
Study NCT00440050 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 placebo capsules twice a day for 18 months
Study NCT03421054 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: patients assuming nutraceutical containing HA
Description: pain reduction of the affected knee in the patients assuming nutraceutical containing HA
Study NCT02911389 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home PT via web-based platform
Study NCT02911389 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home PT via paper manual
Study NCT02911389 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: outpatient PT
Study NCT03645226 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Colonoscopy
Description: All subjects will undergo standard mechanical bowel preparation with 4 liters of polyethylene glycol (Klean-Prep, Norgine Ltd., Middlesex, UK). Total colonoscopy will be performed by experienced endoscopists under conscious sedation with intravenous benzodiazepines and narcotics. A conventional intermediate-length colonoscope (Olympus Corporation, Tokyo, Japan) will be used. One mucosal biopsy will be taken in the descending colon. Biopsies will be performed using standard biopsy forces without needle (Olympus Corporation, Tokyo, Japan). Half of the samples will be immersed in 4 oC normal saline solution. All samples will be immediately sent to pathology department and will be stored in a -80 oC freeze for processing of microbiota analyses.
Study NCT00144521 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTX
Description: 8mg/week(p.o.) for 24 weeks
Study NCT00144521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX placebo
Description: 0mg/week(p.o.) for 24 weeks
Study NCT01902745 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social Cognitive Theory
Description: Social Cognitive Theory of motivating participants to change their behaviors for overall health and well being.
Study NCT02236962 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02236962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ephedrine, pioglitazone
Study NCT00953654 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength Training
Description: 6 weeks of strength training exercise sessions involving leg press, leg curl, and leg extension exercises twice weekly at an intensity progressing from 50% to 75% of predicted one-repetition maximum across the 6 weeks of the trial.
Study NCT00953654 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endurance Training
Description: Six weeks of lower-body dynamic cycling exercise completed on an electronically-braked cycle ergometer twice weekly. The intervention will be matched to the strength training intervention on total work completed, total time actively engaged in exercise, a focus on leg muscles, and load (intensity) progression across the 6 week training protocol.
Study NCT01566266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: 2 capsules of 250mg, 3 times per day during 1 week
Study NCT02232113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CERA
Description: changing frequency of administration from once to twice monthly under a fixed total monthly dose of CERA
Study NCT03753438 — intervention group
Intervention type: PROCEDURE
Intervention: Intragstric Ballooning
Description: Intragstric Ballooning will be put.
Study NCT04455672 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: splints
Description: * Scaning of the maxillary and mandibular cast in the centric relation.~* The CAD/ CAM splints will be designed using Exocad s.~* The design will include all maxillary teeth and the occlusal surfaces will be flat and smooth.~* The difference in design between the ARS and the stabilization splint, is that the ARS will have an anterior ramp to allow for posterior disocclusion of posterior teeth, while the stabilization splint will not have such a pronounced anterior ramp.~* Both splints will be printed using Dent2 3D printer and then cured using Dentcure.~* All patient will be asked to wear their spints during sleeping only.~* In each group, patient will be recalled after 1week,2 weeks 1,2and 3monthes then change for the other splint for another 3 months .
Study NCT04455672 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: splints
Description: * Scaning of the maxillary and mandibular cast in the centric relation.~* The CAD/ CAM splints will be designed using Exocad s.~* The design will include all maxillary teeth and the occlusal surfaces will be flat and smooth.~* The difference in design between the ARS and the stabilization splint, is that the ARS will have an anterior ramp to allow for posterior disocclusion of posterior teeth, while the stabilization splint will not have such a pronounced anterior ramp.~* Both splints will be printed using Dent2 3D printer and then cured using Dentcure.~* All patient will be asked to wear their spints during sleeping only.~* In each group, patient will be recalled after 1week,2 weeks 1,2and 3monthes then change for the other splint for another 3 months .
Study NCT03068338 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic Sock
Description: Soft robotic actuator used in a sock design technology to perform plantarflexion and dorsiflexion of the foot about the ankle joint.
Study NCT03068338 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent pneumatic compression
Description: Conventional device used by hospitals
Study NCT02102308 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Multicomponent exercise
Study NCT02102308 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Education classes
Study NCT04339231 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sphenopalatine ganglion block
Description: The block of the sphenopalatine ganglion will be performed bilaterally, using a cotton bud soaked with 1% ropivacaine, placed in the mucosa of the posterior wall of the nasal cavity, through both nostrils.~Once placed in the proper position, the swab will remain for about 20 minutes to absorb the local anesthetic from the mucosa.
Study NCT04339231 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: sphenopalatine ganglion block
Description: The block of the sphenopalatine ganglion will be performed bilaterally, using a cotton bud soaked with 1% ropivacaine, placed in the mucosa of the posterior wall of the nasal cavity, through both nostrils.~Once placed in the proper position, the swab will remain for about 20 minutes to absorb the local anesthetic from the mucosa.
Study NCT04104581 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Refined Grain Diet
Description: Subjects will be fed the average American diet except it will be free of whole grains
Study NCT04104581 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Whole Grain Oat Diet
Description: Subjects will be fed the average American diet with addition of a low level of whole grain oats
Study NCT04104581 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Whole Grain Oat Diet
Description: Subjects will be fed the average American diet with addition of a high level of whole grain oats
Study NCT04104581 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Whole Grain Wheat Diet
Description: Subjects will be fed the average American diet with addition of a low level of whole grain wheat
Study NCT04104581 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Whole Grain Wheat Diet
Description: Subjects will be fed the average American diet with addition of a high level of whole grain wheat
Study NCT02535208 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Restrictive transfusions based on SCOR assessment
Description: RBC transfusions will be given to subjects either when participants' Hgb levels fall below defined values based on respiratory status or, despite not having reached their Hgb trigger threshold, if they manifest symptoms judged by the clinical care team to be consistent with anemia (i.e. apnea, bradycardia, or desaturation episodes) and subsequently have a NIRS evaluation that demonstrates an SCOR \< 0.73.
Study NCT02535208 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Liberal transfusions
Description: In the liberal group, RBC transfusions will be given to participants when their Hgb level falls below defined values that are based on respiratory support status, as is standard practice.
Study NCT02206503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: This protocol is a phase II multicenter, open label study designed to determine whether the addition of Cyclophosphamide to Rd (CRd) treatment significantly increases response rates and prolonged the outcome (PFS, OS) in patients who experienced a biochemical relapse, without CRAB under Rd treatment. The treatment period includes: administration of the combination CRd for 9 cycles. In order to assess the efficacy and safety of treatment, patients will attend the study center visits at least every 2 weeks. The response will be assessed after each cycle. During the LTFU period, after development of confirmed PD, all patients are to be followed for survival every 1-3 months via telephone or office visit.
Study NCT02206503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Study NCT02206503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study NCT01566266 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: 2 capsules of 250mg, 3 times per day during 1 week
Study NCT01726270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamsulosin
Description: 0.4 mg
Study NCT04059614 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HFNC; COT
Description: HFNC: high-flow nasal cannula therapy COT: conventional oxygen therapy
Study NCT04059614 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HFNC; COT
Description: HFNC: high-flow nasal cannula therapy COT: conventional oxygen therapy
Study NCT03941054 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pressure Release
Description: Subjets receive digitopressure during 90 seconds for the treatment of the Myosfascial Trigger Points
Study NCT02271646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% marcaine 20ml
Description: 3 levels ultrasound guided thoracic paravertebral block at T5-6, T7-8 and T9-10 (total 0.5% marcaine 20ml)